EWTX Edgewise Therapeutics, Inc. Insider Trading

CSO Alan J Russell sold 200,000 shares ($7.9M) on 2026-07-01 per 10b5-1 plan; retains 24,555 non-derivative + 1,077,717 options.

Alan J Russell, Chief Scientific Officer at Edgewise Therapeutics, executed 2 separate sales totaling 200,000 shares for $7,881,401.98 at $39.41 per share on 2026-07-01 as part of a pre-arranged 10b5-1 trading plan. His non-derivative holdings fell from 224.6K shares to 24.6K shares (-89.1%), though he retains 1,077,717 option shares (Table II), so his overall equity exposure remains material. Edgewise is unprofitable (net income $-49.0M over the most recent fiscal year) and trades at $39.56 currently, -10.0% from its 52-week high of $43.93. His prior 5 sales at EWTX have tracked mixed outcomes: the most recent (2025-11-12) saw 90-day post-sale appreciation of +46.8%, while the 2024-12-30 sale declined -15.0% over 90 days, showing no clear directional bias for timing accuracy at this ticker. Because this transaction is scheduled under a 10b5-1 plan rather than discretionary, it does not convey a tactical judgment about price or company direction.

CMO Donovan executes multi-day liquidation totaling ~$2.1M, reducing holdings while stock trades below recent highs amid unprofitable operations.

Joanne M. Donovan, the company's Chief Medical Officer, executed a three-transaction liquidation over two days that removed approximately $2.1 million in value from her holdings. The pattern—two sales bracketing an unusual share acquisition—is noteworthy: the middle transaction (a five-fold increase in holdings at a sharply lower price) suggests either a vesting event or compensatory arrangement that she immediately monetized through a larger subsequent sale. Combined, these moves liquidated the bulk of her position. The timing occurs as the stock trades below its recent highs and the company is unprofitable with widening losses, creating a backdrop where an executive's decision to convert equity into cash warrants investor attention. The scale and speed of this reduction suggests conviction about near-term capital needs or reduced confidence in near-term upside, though the magnitude relative to her role does not suggest crisis-level concern.

CMO Donovan Joanne M. sold 28,662 shares of EWTX at $32.31 via pre-arranged 10b5-1 plan, retaining 9,597 shares

Donovan Joanne M., Chief Marketing Officer, executed a scheduled sale of 28,662 shares under a 10b5-1 trading plan adopted on 2025-12-26, reducing her holdings by 74.9% to 9,597 shares. The sale proceeds totaled $926,095.02 at $32.31 per share. As a pre-arranged plan transaction, the timing and execution reflect a predetermined schedule rather than discretionary trading decisions, limiting inferences about near-term company outlook or insider conviction at the moment of sale. Post-transaction, Donovan retains meaningful ownership with 9,597 shares, indicating continued stake in the company despite the significant reduction in her position.

CMO Donovan sold 21,338 shares at $32.12 under pre-arranged 10b5-1 plan; holdings reduced to 9,597 shares

Donovan Joanne M., Chief Marketing Officer, sold 21,338 shares of EWTX for $685,308.28 on 2026-03-31 pursuant to a 10b5-1 trading plan adopted on 2025-12-26. This is a scheduled transaction rather than a discretionary sale. The sale represents a reduction from 30,935 pre-transaction shares to 9,597 post-transaction shares, a -69.0% decrease in her holdings. Since the trade is pre-arranged under Rule 10b5-1, it reflects a plan established in advance and does not convey timing-based or conviction-driven signals about near-term stock performance.

CMO Joanne M. Donovan sells 16,358 shares of EWTX for $506,734.85 via 10b5-1 plan

Joanne M. Donovan, CMO of Edgewise Therapeutics, executed 2 separate sales totaling 16,358 shares for $506,734.85 on 2026-03-27, reducing her holdings from 25,955 shares to 9,597 shares. This transaction is scheduled under a pre-arranged 10b5-1 trading plan, meaning the sale was determined in advance and not discretionary. The 63.0% reduction in her shareholding is material, though the planned nature of the transaction removes any inference about current sentiment or market view from the timing of the sale.

Director Edris Badreddin sold 115,471 shares (85.4% of prior holdings) for $3.4M under pre-arranged 10b5-1 plan.

Edris Badreddin, a Director at Edgewise Therapeutics, executed 5 separate sales totaling 115,471 shares for $3,399,466.24 at $29.44 per share on 2026-01-21, reducing his holdings from 135,291 shares to 19,820 shares. This transaction was conducted under a pre-arranged 10b5-1 trading plan adopted on 2025-09-24, meaning the sales were scheduled rather than discretionary. The substantial reduction in director ownership (85.4% of prior holdings) reflects execution of a predetermined plan rather than a response to current market conditions or company developments.

Director Fox buys 10,700 shares of EWTX at $18.64; stock now $20.42 (+43.9% from 90-day low), company unprofitable with $-40.7M net loss.

Director Jonathan C Fox purchased 10,700 shares at $18.64 on 2025-11-11, increasing his holdings by 82.3% to 23,702 shares total. This follows a prior buy at the same ticker in 2023 that delivered a 72.1% return over 90 days, and his cross-ticker track record shows 1 prior buy with 100.00% 90-day win rate. However, the company remains unprofitable with a $-40.7M net loss on the most recent full fiscal year, and the stock is currently 43.9% below its 52-week high of $36.38, though up 44.3% over the past 90 days. The timing and sizing of this purchase warrant attention given the insider's prior success at this ticker and the magnitude of the position increase, set against the company's ongoing losses and volatile price recovery.

Chief Scientific Officer Russell Alan J sold 100,000 shares (81.0% of holdings) at $21.12; stock down 43.9% from 52-week high, company unprofitable.

Russell Alan J executed a substantial 100,000-share sale at $21.12 on 2025-11-12, reducing his stake from 123,400 to 23,400 shares (an 81.0% reduction). The transaction occurred against mixed context: while the stock has surged 38.9% over 30 days and 44.3% over 90 days, it remains 43.9% below its 52-week high of $36.38 and trades at $20.42 currently. At the same ticker (EWTX), Russell has executed 5 prior open-market sales; his timing track record there shows mixed results, with 1 of 4 measurable 90-day outcomes well-timed (negative post-sale return). Edgewise reported a negative net income of $-40,666,000.00 over its most recent full fiscal year. The magnitude of the position reduction—81.0% of prior holdings—and the company's unprofitable status warrant attention to whether this reflects a material shift in Russell's assessment of the opportunity.

Chief Scientific Officer Russell Alan J sells 100,000 shares of EWTX at $14.60, reducing stake 81.0%, as stock trades 60.0% below 52-week high.

Russell Alan J, Chief Scientific Officer, sold 100,000 shares (100.0K shares) at $14.60, totaling $1,459,760.00 ($1.5M), reducing his post-transaction holdings to 23,400 shares (23.4K shares) from 123,400 shares (123.4K shares)—a net change of sold 100,000 shares (-81.0% vs pre-transaction holdings). The sale occurs as EWTX trades -60.0% from 52-week high of $36.62 and the company reported net income of $-36,115,000.00 ($-36.1M), indicating continued unprofitability. His prior trades at EWTX show mixed timing outcomes: 1 of 4 prior sells were well-timed at the 90-day mark, with the most recent sale on 2024-12-30 yielding a 90d return of -15.0% (well-timed) but earlier sales producing positive 90d returns. The magnitude of this reduction—divesting 81.0% of holdings—against a backdrop of significant stock depreciation and ongoing losses warrants attention to whether the insider views near-term prospects as constrained.

CMO Donovan sells 25,000 EWTX shares at $27.63; retains 16,358 shares after 60.4% position reduction

Joanne M. Donovan, CMO of Edgewise Therapeutics, sold 25,000 shares at $27.63 on 2025-01-28, reducing her holdings by 60.4% to 16,358 shares. The sale occurred at a price 23.5% below the 52-week high of $36.62, within the company's $15.08–$36.62 annual range. The sale is notable in context of the company's negative financial performance: Edgewise reported net income of $-34,129,000 in its most recent full fiscal year. While the 90-day return of -17.6% followed this insider sale, the significance of this transaction reflects the magnitude of the position reduction and the company's unprofitable status, warranting investor attention to the CMO's conviction level and capital allocation priorities.